More Clinical Lessons from the FIELD Study

@article{Fazio2008MoreCL,
  title={More Clinical Lessons from the FIELD Study},
  author={Sergio Fazio},
  journal={Cardiovascular Drugs and Therapy},
  year={2008},
  volume={23},
  pages={235-241}
}
  • S. Fazio
  • Published 2008
  • Medicine
  • Cardiovascular Drugs and Therapy
IntroductionThe Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study investigated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes.Results and discussionReduction in major coronary events (the primary endpoint) and total cardiovascular disease (CVD) events (the secondary endpoint) was similar (relative risk reduction 11%), but only significant for total CVD events (p = 0.035). The benefit of fenofibrate treatment was greater in patients with mixed… Expand
Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy
TLDR
Current evidence points towards the need to prescribe statins in patients with T2DM before a major decline in kidney function occurs, as well as the role of lipid-lowering drugs (mainly statins) in this field. Expand
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
TLDR
Simvastatin and fenofibrate exhibit a similar effect on the secretory function of human monocytes and lymphocytes and on systemic inflammation in type 2 diabetic subjects with mixed dyslipidemia, and this effect may be clinically relevant in the prevention of vascular complications in metformin- and diet-treated subjects with newly diagnosed diabetic dys Lipidemia. Expand
The Effect of Fenofibrate Treatment on Lipid Profile
Fenofibrate chemically known as 2-[4-(4-chlorobezoyl) phenoxy]-2-methylpropionic acid 1-methylethyl ester, its formula C20H21CIO4, fenofibrate is a lipophilic antihyperlipoproteinemic agent. It is aExpand
A Comprehensive Review on the Drug: Fenofibrate
TLDR
The present review has discussed the historical development, pharmacology, analytical profile with its physicochemical properties and ongoing research scenario on this API. Expand
How to prevent the microvascular complications of type 2 diabetes beyond glucose control
TLDR
Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. Expand
Diabetic retinopathy: A predictor of coronary artery disease
TLDR
Diabetic retinopathy is a good predictor of coronary artery disease that exceeds the conventional risk factors and would benefit from early coronary angiography and diabetic retinocoronary clinics are warranted. Expand
Diabetic cardiomyopathy: signaling defects and therapeutic approaches
TLDR
The impact of hallmark factors in diabetic cardiomyopathy, including dysregulated lipid metabolism, insulin resistance, mitochondrial dysfunction and disturbances in adipokine secretion and signaling are discussed. Expand
Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation.
TLDR
It is hypothesized that glomerular and tubular dysfunction can be induced by increases in intracellular FA concentrations, a process that may be enabled by genetic risk variants, and warrants further investigation. Expand
Synthesis of 5-trifluoromethyl-2-sulfonylpyridine PPARβ/δ antagonists: Effects on the affinity and selectivity towards PPARβ/δ.
TLDR
The synthesis and in vitro biological evaluation of a range of structural analogues of the covalent modification of peroxisome-proliferator activated receptor β/δ demonstrate that an improvement in the selectivity of 5-trifluoromethyl-2-sulfonylpyridine antagonists towards PPARβ/ δ is achievable at the expense of their immediate affinity. Expand

References

SHOWING 1-10 OF 44 REFERENCES
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
TLDR
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. Expand
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
TLDR
Fenofibrate reduces therisk of a first MI and substantially reduces the risk of further clinical CVD events after silent MI, supporting its use in type 2 diabetes. Expand
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
BACKGROUND Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease. In the Diabetes Atherosclerosis Intervention Study (DAIS), treatmentExpand
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
TLDR
Treatment with fenofibrate reduces the angiographic progression of coronary-artery disease in type 2 diabetes, even those previously judged not to need treatment, according to a computer-assisted quantitative approach. Expand
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
TLDR
Among patients with clinically evident CHD and diabetes, intensive therapy with atorvastatin 80 mg significantly reduced the rate of major cardiovascular events by 25% compared with at ORVastatin 10 mg. Expand
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
TLDR
Among people with diabetes the proportional effects of statin therapy were similar irrespective of whether there was a prior history of vascular disease and irrespective of other baseline characteristics and should be considered for all diabetic individuals who are at sufficiently high risk of vascular events. Expand
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
TLDR
Bezafibrate reduces the incidence of MI in patients with MS during long-term follow-up and in 575 patients with augmented features of MS (4-5 risk factors), the remarkable strengthening of cardiac mortality reduction when taking bezfibrate is noted. Expand
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
TLDR
Direct evidence is provided that cholesterol-lowering therapy is beneficial for people with diabetes even if they do not already have manifest coronary disease or high cholesterol concentrations and statin therapy should now be considered routinely for all diabetic patients at sufficiently high risk of major vascular events, irrespective of their initial cholesterol concentrations. Expand
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
TLDR
These data indicate that patients with coronary heart disease and metabolic syndrome derive incremental benefit from high-dose atorvastatin therapy, irrespective of the presence of diabetes. Expand
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
TLDR
Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this effect does not seem to be related to plasma concentrations of lipids. Expand
...
1
2
3
4
5
...